{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:45:19Z","timestamp":1783410319828,"version":"3.54.6"},"reference-count":19,"publisher":"Royal College of General Practitioners","issue":"645","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.3399\/bjgp16x684385","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T05:18:32Z","timestamp":1457673512000},"page":"e241-e247","source":"Crossref","is-referenced-by-count":7,"title":["A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam"],"prefix":"10.3399","volume":"66","author":[{"given":"Ingunn Fride","family":"Tvete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Bj\u00f8rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Skomedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"2019051717454795000_66.645.e241.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03563.x"},{"key":"2019051717454795000_66.645.e241.2","unstructured":"Helsedirektoratet Nasjonal faglig veileder vanedannende legemidler \u2014 rekvirering og forsvarlighet [Health Directorate National academic tutor addictive drugs \u2014 requisitioning and soundness], https:\/\/helsedirektoratet.no\/retningslinjer\/vanedannende-legemidler (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.3","unstructured":"Royal College of Psychiatrists Benzodiazepines, http:\/\/www.rcpsych.ac.uk\/healthadvice\/treatmentswellbeing\/benzodiazepines.aspx (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.4","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418010-00004"},{"key":"2019051717454795000_66.645.e241.5","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.8.1189"},{"key":"2019051717454795000_66.645.e241.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00012995-198606000-00001","article-title":"Adverse effects of prolonged benzodiazepine use","volume":"118","author":"Ashton","year":"1986","journal-title":"Adverse Drug React Bull"},{"key":"2019051717454795000_66.645.e241.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003296"},{"issue":"4","key":"2019051717454795000_66.645.e241.8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/02813432.2015.1117282","article-title":"Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5 year survey. in Norway","volume":"33","author":"Tvete","year":"2015","journal-title":"Scand J Primary Health Care"},{"key":"2019051717454795000_66.645.e241.9","unstructured":"The Norwegian Prescription Database. http:\/\/www.norpd.no (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.10","unstructured":"Statistics Norway. http:\/\/www.ssb.no\/ (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.11","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2009) DDD: Definition and general considerations, http:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/ (accessed Mar 2016)."},{"key":"2019051717454795000_66.645.e241.12","unstructured":"OECD iLibrary OECD economic surveys: Norway 2014, http:\/\/www.oecd-ilibrary.org\/economics\/oecd-economic-surveys-norway-2014_eco_surveys-nor-2014-en (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.13","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427437"},{"issue":"2","key":"2019051717454795000_66.645.e241.14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0022-3565(25)21979-6","article-title":"Comparison of diazepam and oxazepam: preference, liking and extent of abuse","volume":"229","author":"Griffiths","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"2019051717454795000_66.645.e241.15","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology ATC\/DDD index 2016, http:\/\/www.whocc.no\/atc_ddd_index\/ (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.16","unstructured":"(2007) Resource Site for Involuntary Benzodiazepine Tranquilliser Addiction, Withdrawal & Recovery. Benzodiazepine equivalence table, http:\/\/www.benzo.org.uk\/bzequiv.htm (accessed 1 Mar 2016)."},{"key":"2019051717454795000_66.645.e241.17","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050422"},{"issue":"3","key":"2019051717454795000_66.645.e241.18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000092116","article-title":"Socioeconomic influences on benzodiazepine consumption in an Irish Region","volume":"12","author":"Quigley","year":"2006","journal-title":"Eur Addict Res"},{"key":"2019051717454795000_66.645.e241.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0650-y"}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/bjgp16X684385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:55:18Z","timestamp":1748804118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjgp.org\/lookup\/doi\/10.3399\/bjgp16X684385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":19,"journal-issue":{"issue":"645","published-online":{"date-parts":[[2016,3,31]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.3399\/bjgp16X684385"],"URL":"https:\/\/doi.org\/10.3399\/bjgp16x684385","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}